<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p4" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_4{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_4{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_4{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_4{left:341px;bottom:30px;}
#t5_4{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_4{left:377px;bottom:30px;}
#t7_4{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_4{left:540px;bottom:30px;}
#t9_4{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_4{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_4{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_4{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_4{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_4{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_4{left:1111px;bottom:47px;letter-spacing:0.18px;}
#tg_4{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_4{left:267px;bottom:783px;letter-spacing:0.39px;word-spacing:-0.23px;}
#ti_4{left:60px;bottom:764px;letter-spacing:-0.09px;}
#tj_4{left:543px;bottom:746px;letter-spacing:-0.1px;}
#tk_4{left:35px;bottom:128px;}
#tl_4{left:45px;bottom:122px;letter-spacing:0.12px;}
#tm_4{left:859px;bottom:122px;letter-spacing:0.07px;word-spacing:0.01px;}
#tn_4{left:35px;bottom:111px;}
#to_4{left:45px;bottom:105px;letter-spacing:0.12px;}
#tp_4{left:1084px;bottom:83px;letter-spacing:-0.1px;}
#tq_4{left:894px;bottom:514px;letter-spacing:-0.1px;}
#tr_4{left:894px;bottom:496px;letter-spacing:-0.11px;}
#ts_4{left:894px;bottom:473px;letter-spacing:0.15px;}
#tt_4{left:894px;bottom:451px;letter-spacing:-0.2px;}
#tu_4{left:1115px;bottom:459px;}
#tv_4{left:905px;bottom:433px;letter-spacing:-0.18px;}
#tw_4{left:1088px;bottom:441px;letter-spacing:-0.13px;}
#tx_4{left:894px;bottom:410px;letter-spacing:0.16px;}
#ty_4{left:894px;bottom:391px;letter-spacing:-0.17px;}
#tz_4{left:894px;bottom:368px;letter-spacing:0.14px;}
#t10_4{left:894px;bottom:350px;letter-spacing:-0.2px;}
#t11_4{left:1105px;bottom:357px;letter-spacing:-0.41px;}
#t12_4{left:894px;bottom:331px;letter-spacing:-0.18px;}
#t13_4{left:1130px;bottom:337px;letter-spacing:-0.12px;}
#t14_4{left:905px;bottom:313px;letter-spacing:-0.2px;}
#t15_4{left:905px;bottom:295px;letter-spacing:-0.19px;}
#t16_4{left:446px;bottom:287px;letter-spacing:-0.13px;word-spacing:0.03px;}
#t17_4{left:446px;bottom:270px;letter-spacing:-0.1px;}
#t18_4{left:446px;bottom:253px;letter-spacing:-0.1px;}
#t19_4{left:595px;bottom:261px;letter-spacing:-0.12px;}
#t1a_4{left:446px;bottom:230px;letter-spacing:0.15px;}
#t1b_4{left:446px;bottom:214px;}
#t1c_4{left:455px;bottom:214px;letter-spacing:-0.2px;word-spacing:0.02px;}
#t1d_4{left:446px;bottom:197px;}
#t1e_4{left:455px;bottom:197px;letter-spacing:-0.2px;word-spacing:0.01px;}
#t1f_4{left:446px;bottom:170px;letter-spacing:0.14px;}
#t1g_4{left:446px;bottom:154px;}
#t1h_4{left:455px;bottom:154px;letter-spacing:-0.2px;word-spacing:0.02px;}
#t1i_4{left:446px;bottom:514px;letter-spacing:-0.1px;}
#t1j_4{left:521px;bottom:522px;}
#t1k_4{left:529px;bottom:514px;letter-spacing:-0.1px;}
#t1l_4{left:446px;bottom:491px;letter-spacing:0.15px;}
#t1m_4{left:446px;bottom:475px;letter-spacing:-0.19px;}
#t1n_4{left:613px;bottom:482px;letter-spacing:-0.13px;}
#t1o_4{left:457px;bottom:458px;letter-spacing:-0.19px;}
#t1p_4{left:446px;bottom:434px;letter-spacing:0.16px;}
#t1q_4{left:446px;bottom:418px;letter-spacing:-0.2px;}
#t1r_4{left:676px;bottom:425px;letter-spacing:-0.12px;}
#t1s_4{left:446px;bottom:394px;letter-spacing:0.14px;}
#t1t_4{left:446px;bottom:378px;letter-spacing:0.12px;}
#t1u_4{left:675px;bottom:384px;letter-spacing:-0.14px;}
#t1v_4{left:695px;bottom:378px;letter-spacing:0.13px;}
#t1w_4{left:446px;bottom:354px;letter-spacing:0.11px;word-spacing:0.03px;}
#t1x_4{left:446px;bottom:337px;letter-spacing:0.12px;}
#t1y_4{left:446px;bottom:321px;}
#t1z_4{left:455px;bottom:321px;letter-spacing:0.12px;}
#t20_4{left:43px;bottom:513px;letter-spacing:-0.1px;}
#t21_4{left:43px;bottom:490px;letter-spacing:0.15px;}
#t22_4{left:43px;bottom:466px;letter-spacing:0.12px;}
#t23_4{left:268px;bottom:474px;letter-spacing:0.1px;}
#t24_4{left:43px;bottom:449px;letter-spacing:0.12px;}
#t25_4{left:324px;bottom:457px;letter-spacing:0.1px;}
#t26_4{left:43px;bottom:426px;letter-spacing:0.16px;}
#t27_4{left:43px;bottom:403px;letter-spacing:-0.35px;word-spacing:0.01px;}
#t28_4{left:218px;bottom:411px;}
#t29_4{left:223px;bottom:403px;}
#t2a_4{left:228px;bottom:411px;letter-spacing:-0.27px;}
#t2b_4{left:43px;bottom:387px;letter-spacing:-0.35px;}
#t2c_4{left:277px;bottom:394px;}
#t2d_4{left:43px;bottom:363px;letter-spacing:0.13px;}
#t2e_4{left:43px;bottom:346px;letter-spacing:-0.05px;}
#t2f_4{left:260px;bottom:353px;letter-spacing:-0.28px;}
#t2g_4{left:43px;bottom:329px;letter-spacing:-0.34px;}
#t2h_4{left:256px;bottom:337px;letter-spacing:-1.16px;}
#t2i_4{left:43px;bottom:313px;letter-spacing:-0.33px;}
#t2j_4{left:124px;bottom:313px;letter-spacing:-0.34px;}
#t2k_4{left:210px;bottom:320px;letter-spacing:-0.25px;}
#t2l_4{left:43px;bottom:296px;letter-spacing:-0.35px;}
#t2m_4{left:296px;bottom:303px;letter-spacing:-0.25px;}
#t2n_4{left:43px;bottom:279px;letter-spacing:-0.35px;}
#t2o_4{left:259px;bottom:286px;letter-spacing:-1.16px;}
#t2p_4{left:43px;bottom:255px;letter-spacing:0.12px;}
#t2q_4{left:43px;bottom:238px;letter-spacing:0.13px;}
#t2r_4{left:43px;bottom:222px;letter-spacing:0.13px;}
#t2s_4{left:43px;bottom:205px;letter-spacing:0.12px;word-spacing:0.01px;}
#t2t_4{left:315px;bottom:212px;letter-spacing:0.12px;}
#t2u_4{left:43px;bottom:188px;letter-spacing:0.12px;word-spacing:0.01px;}
#t2v_4{left:295px;bottom:196px;letter-spacing:0.11px;}
#t2w_4{left:43px;bottom:171px;letter-spacing:-0.03px;}
#t2x_4{left:331px;bottom:179px;}
#t2y_4{left:54px;bottom:154px;letter-spacing:-0.06px;word-spacing:0.03px;}
#t2z_4{left:43px;bottom:728px;letter-spacing:-0.09px;}
#t30_4{left:54px;bottom:709px;letter-spacing:-0.09px;}
#t31_4{left:54px;bottom:691px;letter-spacing:-0.08px;}
#t32_4{left:43px;bottom:673px;}
#t33_4{left:53px;bottom:673px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t34_4{left:43px;bottom:654px;}
#t35_4{left:53px;bottom:654px;letter-spacing:-0.09px;}
#t36_4{left:54px;bottom:636px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t37_4{left:54px;bottom:618px;letter-spacing:-0.09px;}
#t38_4{left:43px;bottom:599px;letter-spacing:-0.09px;}
#t39_4{left:54px;bottom:581px;letter-spacing:-0.1px;}
#t3a_4{left:133px;bottom:589px;letter-spacing:-0.12px;}
#t3b_4{left:43px;bottom:563px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t3c_4{left:54px;bottom:544px;letter-spacing:-0.11px;word-spacing:0.02px;}
#t3d_4{left:887px;bottom:190px;letter-spacing:-0.09px;}
#t3e_4{left:887px;bottom:171px;letter-spacing:-0.09px;word-spacing:-0.19px;}
#t3f_4{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_4{font-size:28px;font-family:Arial-BoldMT_6y;color:#000;}
.s1_4{font-size:9px;font-family:ArialMT_71;color:#000;}
.s2_4{font-size:5px;font-family:ArialMT_71;color:#000;}
.s3_4{font-size:12px;font-family:Arial-BoldMT_6y;color:#000;}
.s4_4{font-size:17px;font-family:ArialMT_71;color:#0065A4;}
.s5_4{font-size:17px;font-family:Arial-BoldMT_6y;color:#000;}
.s6_4{font-size:12px;font-family:ArialMT_71;color:#000;}
.s7_4{font-size:15px;font-family:ArialMT_71;color:#000;}
.s8_4{font-size:15px;font-family:ArialMT_71;color:#0065A4;}
.s9_4{font-size:17px;font-family:Arial-BoldMT_6y;color:#0065A4;}
.sa_4{font-size:15px;font-family:Arial-BoldMT_6y;color:#000;}
.sb_4{font-size:14px;font-family:ArialMT_71;color:#000;}
.sc_4{font-size:14px;font-family:Arial-BoldMT_6y;color:#000;}
.sd_4{font-size:15px;font-family:ArialMT_79;color:#000;}
.se_4{font-size:17px;font-family:Arial-BoldMT_7h;color:#000;}
.sf_4{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts4" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_6y;
	src: url("fonts/Arial-BoldMT_6y.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_7h;
	src: url("fonts/Arial-BoldMT_7h.woff") format("woff");
}

@font-face {
	font-family: ArialMT_71;
	src: url("fonts/ArialMT_71.woff") format("woff");
}

@font-face {
	font-family: ArialMT_79;
	src: url("fonts/ArialMT_79.woff") format("woff");
}

</style>
<div id="pg4Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg4" style="-webkit-user-select: none;"><object width="1210" height="935" data="4/4.svg" type="image/svg+xml" id="pdf4" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_4" class="t s0_4">NCCN Guidelines Version 4.2024 </span>
<span id="t2_4" class="t s0_4">Head and Neck Cancers </span>
<span id="t3_4" class="t s1_4">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_4" class="t s2_4">® </span>
<span id="t5_4" class="t s1_4">(NCCN </span>
<span id="t6_4" class="t s2_4">® </span>
<span id="t7_4" class="t s1_4">), All rights reserved. NCCN Guidelines </span>
<span id="t8_4" class="t s2_4">® </span>
<span id="t9_4" class="t s1_4">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_4" class="t s3_4">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_4" class="t s3_4">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_4" class="t s4_4">NCCN Guidelines Index </span>
<span id="td_4" class="t s4_4">Table of Contents </span>
<span id="te_4" class="t s4_4">Discussion </span>
<span id="tf_4" class="t s5_4">SYST-A </span>
<span id="tg_4" class="t s5_4">1 OF 4 </span>
<span id="th_4" class="t s5_4">PRINCIPLES OF SYSTEMIC THERAPY FOR NON-NASOPHARYNGEAL CANCERS </span>
<span id="ti_4" class="t s5_4">(Oral Cavity [including mucosal lip], Oropharynx, Hypopharynx, Glottic Larynx, Supraglottic Larynx, Ethmoid Sinus, Maxillary Sinus, and </span>
<span id="tj_4" class="t s5_4">Occult Primary) </span>
<span id="tk_4" class="t s6_4">a </span>
<span id="tl_4" class="t s7_4">The categories of evidence and consensus for induction therapy vary depending on site. See disease-specific site in the </span><span id="tm_4" class="t s8_4">Head and Neck Table of Contents. </span>
<span id="tn_4" class="t s6_4">b </span>
<span id="to_4" class="t s7_4">Adverse pathologic features: extranodal extension and/or positive margins or close margins. </span>
<span id="tp_4" class="t s9_4">References </span>
<span id="tq_4" class="t s5_4">Postoperative Systemic </span>
<span id="tr_4" class="t s5_4">Therapy/RT </span>
<span id="ts_4" class="t sa_4">Preferred Regimens </span>
<span id="tt_4" class="t s7_4">• Cisplatin (category 1 for high-risk </span>
<span id="tu_4" class="t s6_4">b </span>
<span id="tv_4" class="t s7_4">non-oropharyngeal cancers) </span>
<span id="tw_4" class="t s6_4">25-30 </span>
<span id="tx_4" class="t sa_4">Other Recommended Regimens </span>
<span id="ty_4" class="t s7_4">• None </span>
<span id="tz_4" class="t sa_4">Useful in Certain Circumstances </span>
<span id="t10_4" class="t s7_4">• Docetaxel (if cisplatin ineligible) </span>
<span id="t11_4" class="t sb_4">10 </span>
<span id="t12_4" class="t s7_4">• Docetaxel/cetuximab (category 2B) </span>
<span id="t13_4" class="t s6_4">31 </span>
<span id="t14_4" class="t s7_4">(if cisplatin ineligible and extranodal </span>
<span id="t15_4" class="t s7_4">extension and/or positive margins) </span>
<span id="t16_4" class="t s5_4">Systemic Therapy/RT Following Induction Therapy, </span>
<span id="t17_4" class="t s5_4">or Combination Chemotherapy for Recurrent/ </span>
<span id="t18_4" class="t s5_4">Persistent Disease </span>
<span id="t19_4" class="t sc_4">2,23,24 </span>
<span id="t1a_4" class="t sa_4">Preferred Regimens </span>
<span id="t1b_4" class="t s7_4">• </span><span id="t1c_4" class="t sd_4">Weekly carboplatin + concurrent RT </span>
<span id="t1d_4" class="t s7_4">• </span><span id="t1e_4" class="t sd_4">Weekly cisplatin (category 2B) + concurrent RT </span>
<span id="t1f_4" class="t sa_4">Useful in Certain Circumstances Regimens </span>
<span id="t1g_4" class="t s7_4">• </span><span id="t1h_4" class="t sd_4">Weekly cetuximab + concurrent RT </span>
<span id="t1i_4" class="t s5_4">Induction </span>
<span id="t1j_4" class="t sc_4">a </span>
<span id="t1k_4" class="t se_4">/Sequential Systemic Therapy </span>
<span id="t1l_4" class="t sa_4">Preferred Regimens </span>
<span id="t1m_4" class="t s7_4">• Docetaxel/cisplatin/5-FU </span>
<span id="t1n_4" class="t s6_4">17-20 </span>
<span id="t1o_4" class="t s7_4">(category 1 if induction is chosen) </span>
<span id="t1p_4" class="t sa_4">Other Recommended Regimens </span>
<span id="t1q_4" class="t s7_4">• Paclitaxel/cisplatin/infusional 5-FU </span>
<span id="t1r_4" class="t s6_4">21 </span>
<span id="t1s_4" class="t sa_4">Useful in Certain Circumstances </span>
<span id="t1t_4" class="t s7_4">• Carboplatin/paclitaxel/cetuximab </span>
<span id="t1u_4" class="t sb_4">22 </span>
<span id="t1v_4" class="t s7_4">(category 2B) </span>
<span id="t1w_4" class="t sa_4">For Newly Diagnosed T3, T4a Ethmoid Sinus Tumor </span>
<span id="t1x_4" class="t s7_4">• Etoposide/cisplatin (category 2B) </span>
<span id="t1y_4" class="t s7_4">• </span><span id="t1z_4" class="t sd_4" data-mappings='[[20,"fl"]]'>Docetaxel/cisplatin/ﬂuorouracil (category 2B). </span>
<span id="t20_4" class="t s5_4">Primary Systemic Therapy + Concurrent RT </span>
<span id="t21_4" class="t sa_4">Preferred Regimens </span>
<span id="t22_4" class="t s7_4">• High-dose cisplatin (category 1) </span>
<span id="t23_4" class="t s6_4">3,4 </span>
<span id="t24_4" class="t s7_4">• Carboplatin/infusional 5-FU (category 1) </span>
<span id="t25_4" class="t s6_4">5,6 </span>
<span id="t26_4" class="t sa_4">Other Recommended Regimens </span>
<span id="t27_4" class="t s7_4">• Weekly cisplatin (40 mg/m </span>
<span id="t28_4" class="t s1_4">2 </span>
<span id="t29_4" class="t s7_4">) </span>
<span id="t2a_4" class="t s6_4">7,8 </span>
<span id="t2b_4" class="t s7_4">• Carboplatin/paclitaxel (category 2B) </span>
<span id="t2c_4" class="t s6_4">9 </span>
<span id="t2d_4" class="t sa_4">Useful in Certain Circumstances </span>
<span id="t2e_4" class="t s7_4">• Docetaxel (if cisplatin ineligible) </span>
<span id="t2f_4" class="t sb_4">10 </span>
<span id="t2g_4" class="t s7_4">• 5-FU/hydroxyurea (category 2B) </span>
<span id="t2h_4" class="t s6_4">11 </span>
<span id="t2i_4" class="t s7_4">• Cetuximab </span><span id="t2j_4" class="t s7_4">(category 2B) </span>
<span id="t2k_4" class="t s6_4">12 </span>
<span id="t2l_4" class="t s7_4">• Cisplatin/infusional 5-FU (category 2B) </span>
<span id="t2m_4" class="t s6_4">13 </span>
<span id="t2n_4" class="t s7_4">• Cisplatin/paclitaxel (category 2B) </span>
<span id="t2o_4" class="t s6_4">11 </span>
<span id="t2p_4" class="t s7_4">Select ethmoid/maxillary sinus cancers (ie, small cell, </span>
<span id="t2q_4" class="t s7_4">SNEC, high-grade olfactory esthesioneuroblastoma, </span>
<span id="t2r_4" class="t s7_4">SNUC with neuroendocrine features): </span>
<span id="t2s_4" class="t s7_4">• Carboplatin/etoposide ± concurrent RT </span>
<span id="t2t_4" class="t s6_4">14 </span>
<span id="t2u_4" class="t s7_4">• Cisplatin/etoposide ± concurrent RT </span>
<span id="t2v_4" class="t s6_4">14,15 </span>
<span id="t2w_4" class="t s7_4">• Cyclophosphamide/doxorubicin/vincristine </span>
<span id="t2x_4" class="t s6_4">16 </span>
<span id="t2y_4" class="t s7_4">(followed by RT-based treatment) (category 2B) </span>
<span id="t2z_4" class="t s5_4">• The choice of systemic therapy should be individualized based on patient characteristics (eg, PS, goals of therapy). Next-generation </span>
<span id="t30_4" class="t se_4" data-mappings='[[28,"fi"]]'>sequencing (NGS) genomic proﬁling, including testing for combined positive score (CPS), may be considered to guide patient treatment </span>
<span id="t31_4" class="t s5_4">options, including clinical trials. </span>
<span id="t32_4" class="t s5_4">• </span><span id="t33_4" class="t se_4" data-mappings='[[45,"fi"]]'>The preferred chemoradiotherapy approach for ﬁt patients with locally advanced disease remains concurrent cisplatin and radiotherapy. </span>
<span id="t34_4" class="t s5_4">• </span><span id="t35_4" class="t se_4">Cisplatin-based induction chemotherapy can be used, followed by radiation-based locoregional treatment (ie, sequential chemoRT). </span>
<span id="t36_4" class="t s5_4">However, an improvement in overall survival with the incorporation of induction chemotherapy compared to proceeding directly to state-of- </span>
<span id="t37_4" class="t s5_4">the-art concurrent chemoRT (cisplatin preferred, category 1) has not been established in randomized studies. </span>
<span id="t38_4" class="t s5_4">• Cisplatin-based induction chemotherapy followed by high-dose, every-3-week cisplatin chemoradiotherapy is associated with toxicity </span>
<span id="t39_4" class="t s5_4">concerns. </span>
<span id="t3a_4" class="t sc_4">1,2 </span>
<span id="t3b_4" class="t s5_4">• After induction chemotherapy, multiple options can be used for the radiation-based portion of therapy, including radiotherapy alone, </span>
<span id="t3c_4" class="t s5_4">particularly for patients with CR after induction chemotherapy. </span>
<span id="t3d_4" class="t s9_4">Regimens for Recurrent, </span>
<span id="t3e_4" class="t s9_4">Unresectable, or Metastatic Disease </span>
<span id="t3f_4" class="t sf_4">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
